Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.
Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.